机构:[1]Department of Ophthalmology, Peking University People’s Hospital, No.11 Xizhimen South Street, Beijing 100044, China.[2]Eye Diseases and Optometry Institute, Beijing, China.[3]Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing, China.[4]College of Optometry, Peking University Health Science Center, Beijing, China.
This study was supported by the National Key R&D Program of China (No.
2020YFC2008200) and Capital Clinical Diagnosis and Treatment Technology
Research and Demonstration Application Project of China (Grant:
Z191100006619029).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类|4 区医学
小类|4 区眼科学
最新[2023]版:
大类|4 区医学
小类|3 区眼科学
第一作者:
第一作者机构:[1]Department of Ophthalmology, Peking University People’s Hospital, No.11 Xizhimen South Street, Beijing 100044, China.[2]Eye Diseases and Optometry Institute, Beijing, China.[3]Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing, China.[4]College of Optometry, Peking University Health Science Center, Beijing, China.
通讯作者:
推荐引用方式(GB/T 7714):
Tang Jiyang,Han Xinyao,Tang Ran,et al.Case series: pachychoroid pigment epitheliopathy transformed to polypoidal choroidal vasculopathy after long-term follow-up.[J].BMC ophthalmology.2022,22(1):272.doi:10.1186/s12886-022-02487-8.
APA:
Tang Jiyang,Han Xinyao,Tang Ran,Li Mengyang,Wang Zongyi...&Qu Jinfeng.(2022).Case series: pachychoroid pigment epitheliopathy transformed to polypoidal choroidal vasculopathy after long-term follow-up..BMC ophthalmology,22,(1)
MLA:
Tang Jiyang,et al."Case series: pachychoroid pigment epitheliopathy transformed to polypoidal choroidal vasculopathy after long-term follow-up.".BMC ophthalmology 22..1(2022):272